Encorafenib (Braftovi®), binimetinib (Mektovi®) for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||08/01/2019|
|Rapid review completed||23/01/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of encorafenib and binimetinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations; May 2019